Halozyme Therapeutics

HALO82

High Quality

$48.19arrow_drop_up0.87%$0.42

High Quality

HALO82

$48.19

arrow_drop_up0.87%$0.42

High Quality

Performance History

Key Stats
Open	$47.78
Prev. Close	$47.79
EPS	3.02
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	47.37	48.33
52 Week Range	32.83	65.53

Ratios







EPS	3.02

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Halozyme Therapeutics (HALO)

Halozyme Therapeutics Inc (HALO) is a biotechnology company that focuses on developing and commercializing novel oncology therapies. The company's flagship product, ENHANZE, is a proprietary technology platform designed to improve the delivery and effectiveness of biologics through the power of hyaluronidase. By breaking down the barriers of the extracellular matrix, ENHANZE enables the rapid and uniform dispersion of therapeutic molecules, allowing for more targeted and efficient treatment options for patients.

Halozyme Therapeutics' stock price history has seen its ups and downs over the years. In 2020, the stock experienced a significant drop due to the market volatility caused by the COVID-19 pandemic. However, it has shown signs of recovery in recent months, thanks to positive clinical trial results and the successful launch of new products. As of the latest trading session, HALO stock is trading at $25.50 per share, reflecting a market capitalization of $4.62 billion.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Headquarters: San Diego
Employees: 393
Exchange: NASDAQ

Keep an eye on Halozyme Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Halozyme Therapeutics 's (HALO) price per share?

The current price per share for Halozyme Therapeutics (HALO) is $48.19. The stock has seen a price change of $0.42 recently, indicating a 0.88% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Halozyme Therapeutics (HALO)?

For Halozyme Therapeutics (HALO), the 52-week high is $65.53, which is 35.98% from the current price. The 52-week low is $32.83, the current price is 46.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Halozyme Therapeutics (HALO) a growth stock?

Halozyme Therapeutics (HALO) has shown an average price growth of -3.72% over the past three years. It has received a score of 72 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Halozyme Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Halozyme Therapeutics (HALO) stock price performance year to date (YTD)?

As of the latest data, Halozyme Therapeutics (HALO) has a year-to-date price change of 28.88%. Over the past month, the stock has experienced a price change of -4.5%. Over the last three months, the change has been -22.47%. Over the past six months, the figure is 11.86%. Looking at a longer horizon, the five-year price change stands at 146.75%.

help

Is Halozyme Therapeutics (HALO) a profitable company?

Halozyme Therapeutics (HALO) has a net income of $281.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 76.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 56.26% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $829.25M, with a revenue growth rate of 25.62%, providing insight into the company's sales performance and growth. The gross profit is $636.89M. Operating income is noted at $337.57M. Furthermore, the EBITDA is $558.6M.

help

What is the market capitalization of Halozyme Therapeutics (HALO)?

Halozyme Therapeutics (HALO) has a market capitalization of $6.04B. The average daily trading volume is 47.94, indicating the stock's liquidity and investor engagement.